Hydrogen-1 MR spectroscopy for measurement and diagnosis of hepatic steatosis
- PMID: 22733887
- PMCID: PMC3422734
- DOI: 10.2214/AJR.11.7384
Hydrogen-1 MR spectroscopy for measurement and diagnosis of hepatic steatosis
Abstract
Objective: Hydrogen-1 MR spectroscopy ((1)H-MRS) is gaining acceptance as a noninvasive technique for assessment of hepatic steatosis, and the findings have been found to correlate closely with histopathologic grade. The aims of this study were to validate (1)H-MRS performed with a 3-T MRI system for quantifying hepatic steatosis and to determine threshold values of (1)H-MRS proton density fat fraction corresponding to standard histopathologic grade in patients undergoing diagnostic liver biopsy.
Subjects and methods: We conducted a prospective cross-sectional liver MRS study with 52 subjects undergoing diagnostic liver biopsy. The diagnostic accuracy of (1)H-MRS was evaluated with receiver operating characteristic curves.
Results: The diagnostic accuracy of (1)H-MRS for hepatic steatosis was high with an area under the receiver operating characteristic curve of 0.94 (95% CI, 0.88-1.0). Results were similar for three (1)H-MRS measurements obtained at different locations in the liver, for two independent pathologists, and whether fibrosis was present or absent. One third of participants had elevated transaminase concentrations of unknown cause, and (1)H-MRS estimates of steatosis had perfect agreement with histopathologic grade in this group. Calculated (1)H-MRS proton density fat fraction thresholds for histologic grades were less than 17% for grade 0 or trace steatosis, 17-38.6% for grade 1, and greater than 38.6% for grade 2 or higher.
Conclusion: Hydrogen-1 MR spectroscopy is an effective, noninvasive technique that can be used to diagnose and quantify hepatic steatosis. Hydrogen-1 MR spectroscopy thresholds corresponded with histopathologic grades and may be useful in the workup of patients with elevated transaminase concentrations.
Trial registration: ClinicalTrials.gov NCT00594412.
Figures


Similar articles
-
Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy.Radiology. 2010 Jul;256(1):159-68. doi: 10.1148/radiol.10091790. Radiology. 2010. PMID: 20574093
-
Quantification of hepatic steatosis: a comparison of the accuracy among multiple magnetic resonance techniques.J Gastroenterol Hepatol. 2014 Apr;29(4):807-13. doi: 10.1111/jgh.12451. J Gastroenterol Hepatol. 2014. PMID: 24224538
-
Hepatic steatosis in morbidly obese patients undergoing gastric bypass surgery: assessment with open-system 1H-MR spectroscopy.AJR Am J Roentgenol. 2011 Jun;196(6):W736-42. doi: 10.2214/AJR.10.5215. AJR Am J Roentgenol. 2011. PMID: 21606262
-
Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis.Eur Radiol. 2019 Jul;29(7):3564-3573. doi: 10.1007/s00330-019-06072-4. Epub 2019 Mar 21. Eur Radiol. 2019. PMID: 30899974 Review.
-
Recent advances in imaging hepatic fibrosis and steatosis.Expert Rev Gastroenterol Hepatol. 2011 Feb;5(1):91-104. doi: 10.1586/egh.10.85. Expert Rev Gastroenterol Hepatol. 2011. PMID: 21309675 Review.
Cited by
-
4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics.EPMA J. 2014 Dec 7;5(1):21. doi: 10.1186/1878-5085-5-21. eCollection 2014. EPMA J. 2014. PMID: 25937854 Free PMC article. Review.
-
Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.Growth Horm IGF Res. 2017 Dec;37:1-6. doi: 10.1016/j.ghir.2017.10.002. Epub 2017 Oct 7. Growth Horm IGF Res. 2017. PMID: 29031905 Free PMC article. Clinical Trial.
-
Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection.AIDS Res Hum Retroviruses. 2015 Oct;31(10):961-6. doi: 10.1089/AID.2015.0093. Epub 2015 Aug 24. AIDS Res Hum Retroviruses. 2015. PMID: 26214341 Free PMC article. Clinical Trial.
-
The effects of ellagic acid in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a randomized, add-on, double-blind, controlled trial.Inflammopharmacology. 2025 Aug 28. doi: 10.1007/s10787-025-01919-3. Online ahead of print. Inflammopharmacology. 2025. PMID: 40877731
-
Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease.J Clin Transl Hepatol. 2018 Jun 28;6(2):217-221. doi: 10.14218/JCTH.2018.00021. Epub 2018 Jun 22. J Clin Transl Hepatol. 2018. PMID: 29951367 Free PMC article. Review.
References
-
- Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–1231. - PubMed
-
- Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288:E462–E468. - PubMed
-
- Krssák M, Hofer H, Wrba F, et al. Non-invasive assessment of hepatic fat accumulation in chronic hepatitis C by 1H magnetic resonance spectroscopy. Eur J Radiol. 2010;74:e60–e66. - PubMed
-
- Orlacchio A, Bolacchi F, Cadioli M, et al. Evaluation of the severity of chronic hepatitis C with 3-T 1H-MR spectroscopy. AJR. 2008;190:1331–1339. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical